Cancer
Reminder!
The tier level is assigned to the guideline, NOT to the specific search terms. For example, a Tier 1 guideline has at least one recommendation that meets criteria for Tier 1, but also could include tier 2 or 3 recommendations.
DO read the guidelines to find out about specific search terms.
DON’T rely on the overall tier classification of the guideline for the specified search terms.
See More FAQ
| Publication | Tier |
|---|---|
|
Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
The U.S. Food and Drug Administration (FDA) |
|
|
Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.
Emons Günter et al. Geburtshilfe und Frauenheilkunde 2018 Oct 78(10) 949-971 |
|
|
Local Coverage Determination (LCD) for Genetic Testing for Lynch Syndrome
The Centers for Medicare & Medicaid Services (CMS) |
|
|
Committee opinion no. 634: hereditary cancer syndromes and risk assessment.
Obstet Gynecol 2015 Jun 125(6) 1538-43 |
|
|
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.
|
|
|
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.
Vasen HF, et al. Gut. 2013 Jun;62(6):812-23 |
|